CRISPR, the gene-editing technology which won its creators the 2020 Nobel Prize for Chemistry, is most well-known for its ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

Despite a challenging CASGEVY launch, high cash burn, and an almost 10% YTD share count growth, CRISPR’s pipeline breadth and ...

Investors seeking stocks with explosive growth potential should consider the biotech industry. Drugmakers can experience ...

Cambridge-based Fulcrum Therapeutics said it will aim to launch a large clinical trial in the second half of 2026 to prove ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

A team of researchers at the Icahn School of Medicine at Mount Sinai has uncovered why children with the same ...

A recent study in the journal PNAS from the lab of Julie Overbaugh reveals a previously unknown antiviral function of a gene ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...